Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Gemcitabine in Refractory Pancreatic Cancer and Sarcoma
NCT02959164Phase 1Completed
- Start
- Dec 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of decitabine in pancreatic ductal adenocarcinoma (PDAC) and sarcoma. Primary endpoints: Dose Limiting Toxicity at 30 days and Tumor Response Rate at 8 weeks. Started Dec 2016; status: completed.
02
Drugs
decitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)sarcoma
Beyond the preview
Go deeper on NCT02959164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959164.